筛查乳腺X线召回加速诊断路径的及时性研究
该回顾性研究比较了加速与标准筛查乳腺X线召回路径的诊断及时性、恶性检出率及癌症特征。加速路径由放射科医生标记高度可疑BI-RADS 0病灶并电话预约,目标一周内完成诊断评估。结果显示加速路径缩短了筛查至诊断、诊断至活检及筛查至活检间隔,延迟检查更少,恶性检出率更高。
要点
- 放射科医生可标记高度可疑BI-RADS 0病灶进入加速路径,缩短诊断等待时间。
- 加速路径筛查至诊断中位7天,标准路径25天,延迟诊断比例显著降低。
- 加速路径恶性检出率极高(PPV1 91.2%,PPV3 94.5%),支持资源优先分配。
关键影像表现/征象
- 加速路径患者年龄更大(中位64.6岁 vs 52.5岁,p<0.001)。
- 加速路径BI-RADS 4/5比例更高(96.5% vs 30.1%,p<0.001)。
- 多变量逻辑回归显示肿块征象(OR 3.36,p<0.001)和影像大小(每mm OR 1.03,p=0.003)是加速路径预测因素。
诊断标准与关键数值
- 加速路径筛查至诊断中位7天 vs 25天,诊断至活检14天 vs 19天,筛查至活检24天 vs 45天(均p<0.001)。
- 延迟诊断影像(筛查后≥30天)加速路径7.0% vs 标准路径38.2%(p<0.001)。
- 延迟活检(诊断后≥30天)加速路径1.8% vs 标准路径14.5%(p=0.004)。
- 恶性检出率:PPV1加速路径91.2% vs 标准路径5.2%;PPV3加速路径94.5% vs 标准路径18.2%(p<0.001)。
临床应用与阅片要点
- 在日常阅片中可对高度可疑BI-RADS 0病灶(如肿块、较大影像尺寸)标记加速路径,优先安排诊断评估。
- 加速路径有助于减少延迟诊断和活检,提高恶性检出效率,但需注意其针对高度选择人群。
局限性
- 回顾性单中心设计,加速路径样本量较小(57例),可能存在选择偏倚。
- 排除247例无随访标准路径病例,可能影响比较的完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare diagnostic and biopsy timeliness, malignancy yield, and cancer characteristics between expedited and standard screening mammography recall pathways.
METHODS: An expedited recall workflow implemented in Epic enabled radiologists to flag highly suspicious BI-RADS 0 findings for telephone scheduling into reserved appointments, targeting diagnostic evaluation within one week. We retrospectively reviewed recalls from 11/1/2024-1/31/2026. Primary outcomes were time from screening to diagnostic evaluation and malignancy yield (PPV1 and PPV3). Secondary outcomes included diagnostic-to-biopsy and screening-to-biopsy intervals, delayed diagnostic imaging (≥30 days from screening), delayed biopsy (≥30 days from diagnostic), and malignancy characteristics. Intervals were measured in calendar days.
RESULTS: Among 36,384 screening mammograms, 4,647 were BI-RADS 0 (recall rate 12.8%); 57 (1.2%) were expedited. After excluding 247 standard pathway cases without follow-up, 4,400 were analyzed. Expedited patients were older (median 64.6 vs 52.5 years, p<0.001) with shorter median screening-to-diagnostic (7 vs 25 days), diagnostic-to-biopsy (14 vs 19 days), and screening-to-biopsy intervals (24 vs 45 days; all p<0.001). Delayed diagnostic imaging (7.0% vs 38.2%, p<0.001) and biopsy (1.8% vs 14.5%, p=0.004) were less frequent. Expedited cases had higher BI-RADS 4/5 rates (96.5% vs 30.1%, p<0.001) and malignancy yield (PPV1 91.2% vs 5.2%; PPV3 94.5% vs 18.2%; p<0.001). Multivariable logistic regression among 278 cancers identified mass findings (OR 3.36, p<0.001) and imaging size (OR 1.03/mm, p=0.003) as predictors of expedited routing.
DISCUSSION: Radiologists identified highly suspicious screening mammography findings for expedited evaluation. Expedited routing was associated with shorter diagnostic and biopsy intervals and high malignancy yield, supporting diagnostic resource prioritization.
引用
- Panigrahi B, Raman S, Mullen LA, et al. Timeliness of an Expedited Diagnostic Pathway for Screening Mammography Recalls. J Am Coll Radiol. 2026. PMID: 42918472. doi:10.1016/j.jacr.2026.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。